In the same year (2019), subcutaneous administration of Poly I:C- or IFN-γ-primed Wharton’s jelly-derived MSCs (WJ-MSCs) improved the therapeutic effects in a murine AD model [156]. This evidence concerns the gene IFNG and Alzheimer disease.